<DOC>
	<DOCNO>NCT00058825</DOCNO>
	<brief_summary>Patients ask participate study cancer blood , Fanconi 's Anemia , unsuccessfully treat bone marrow failure Aplastic Anemia Paroxysmal Nocturnal Hemoglobinuria . Any condition could benefit allogeneic stem cell transplant use donor related patient . Stem cell create bone marrow . They grow different type blood cell patient need , include red blood cell , white blood cell , platelet . In transplant , patient 's stem cell kill replaced stem cell donor . Usually , patient give strong dos chemotherapy prior receive stem cell transplant . However , patient 's condition , high risk experience life-threatening treatment-related side-effects . Recently , doctor begin use chemotherapy cause many side-effects patient receive transplant . This research study add CAMPATH 1H low-dose chemotherapy regimen , follow allogeneic stem cell transplantation . We want see whether add CAMPATH 1H transplant medication help treat disease . We also want see whether few life-threatening side-effects treatment . CAMPATH 1H drug still study . CAMPATH 1H stay active body long time patient receive , mean may work long prevent graft-versus-host-disease ( GvHD ) symptom .</brief_summary>
	<brief_title>Stem Cell Transplant Hematologic Diseases</brief_title>
	<detailed_description>Before treatment begin , stem cell collect donor 's blood bone marrow . The stem cell collect frozen start give patient chemotherapy . After admission hospital , patient receive total body irradiation ( strong x-ray kill cell bone marrow ) , Fludarabine Campath 1H prior stem cell transplant ( infusion donor 's stem cell ) . Starting 7 day transplant , patient give G-CSF subcutaneous injection , blood test show number granulocyte ( type white blood cell ) blood 1,000/uL . This help increase blood cell count . After transplantation , patient undergo several evaluation different time . These standard evaluation test perform patient received stem cell transplant , part routine clinical monitoring . We also look patient 's immune function ( body protect prevent fight infection disease ) . To , blood test perform regular interval ( every 3 6 month ) 2 year . Depending well donor stem cell work body transplant , patient may receive one Donor Leukocyte Infusions ( DLI ) . This leukocytes ( type white blood cell ) collect donor provide stem cell give patient central line vein .</detailed_description>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Diagnosis myelodysplastic disorder ; Fanconi 's Anemia ; Acute Myelogenous Leukemia ( include secondary ) ; Acute Lymphoblastic Leukemia ; Multiple Myeloma ; Plasma Cell Dyscrasia ; lymphoproliferative disorder ( NonHodgkin Lymphoma , Hairy Cell Leukemia , Chronic Lymphocytic Leukemia , Hodgkin 's Disease ) . Diagnosis myelodysplastic disorder good risk IPSS : Fanconi 's Anemia ; Acute Myelogenous Leukemia ( 1st subsequent relapse , 2nd subsequent CR , refractory disease ) ; Acute Lymphoblastic Leukemia 2nd subsequent remission relapse refractory disease ; Philadelphia Chromosomepositive Chronic Myelogenous Leukemia ( fail STI interferon ) ; Multiple Myeloma ( Stage II III ) ; Lymphoma ; Chronic Lymphocytic Leukemia ( primary refractory recurrent disease ) ; Hodgkin 's Disease ( relapse ) ; Hemophagocytic Lymphohistiocytosis ( fail chemotherapy and/or antiviral therapy ) ; bone marrow failure Aplastic Anemia Paroxysmal Nocturnal Hemoglobinuria ; PNH ( fail prior therapy ) . 2 . Conditions increase treatment related mortality : ( need one eligible ) : Age &gt; / = 50 year ; EF le 45 % ; DLCO le 50 % FEVI 5075 % predict value ; Diabetes Mellitus ; Renal Insufficiency ( creatinine clearance le 25 mL/min ) ; Prior recent history systemic fungal infection ; 3rd great remission AML ALL ; Significant Grade III IV neurologic hepatic toxicity previous treatment ; More 1 year diagnosis ( CML Myeloma patient ONLY ) ; Multiple type treatment regimen ( equal 3 ) ; Significant Grade III IV neurologic hepatic toxicity previous treatment ; Prior autologous allogeneic stem cell transplantation . 3 . Haploidentical family member donor . This protocol open patient lack 5/6 6/6 HLA antigenmatched donor . Due increase risk GvHD , patient Fanconi Anemia 5/6 HLA match also eligible . For protocol , `` best '' donor define firstdegree haploidentical family member match greatest number MHC locus . Matching determined Class I Class II DNA type . The donor sufficiently healthy increase risk stem cell mobilization procedure . Should one `` equally '' MHCincompatible donor identify , selection criterion include : age size donor , CMV status , sex . The Principal Investigator make final decision . 4 . Available healthy donor without contraindication donation . 5 . Patient and/or legal representative and/or legal guardian able understand sign consent . 6 . Age birth 70 year . 7 . Women childbearing potential must negative pregnancy test . EXCLUSION CRITERIA : 1 . Pregnant , lactate unwilling use contraception . 2 . HIVpositive patient . 3 . Uncontrolled intercurrent infection . 4 . Untreated blast crisis CML . 5 . Uncontrolled highgrade lymphoproliferative disease / lymphoma . 6 . Unstable angina uncompensated congestive heart failure ( Zubrod 3 great ) . 7 . Severe chronic pulmonary disease require oxygen ( Zubrod 3 great ) . 8 . Hemodialysis dependent . 9 . Active hepatitis cirrhosis total bilirubin , SGOT , SGPT great 3X upper limit normal . 10 . Unstable cerebral vascular disease recent hemorrhagic stroke ( le 6 month ) . 11 . Active CNS disease hematological disorder .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Campath</keyword>
	<keyword>stem cell transplant</keyword>
</DOC>